Syncona Limited is a healthcare investment company that focuses on developing and commercializing innovative therapies for patients with serious medical conditions. The company was founded in 2012 and is based in London, United Kingdom. Syncona is committed to investing in companies that have the potential to make a significant impact in the healthcare industry, particularly in the areas of gene therapy, cell therapy, and small molecule therapeutics. The company has a strong track record of partnering with leading scientists and entrepreneurs to build successful companies that deliver meaningful benefits to patients. With a long-term investment horizon and a patient capital approach, Syncona is dedicated to creating sustainable value for all stakeholders.
